Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
 - EconoTimes)
NEW ORLEANS, Aug. 11, 2017 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 29, 2017 to file lead plaintiff applications in a securities class action lawsuit against IntelliPharmaCeutics International, Inc. (NasdaqCM:IPCI), if they purchased the Company’s shares between January 14, 2016 and July 26, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Get Help
IntelliPharmaCeutics investors should visit us at https://www.claimsfiler.com/cases/view-intellipharmaceutics-international-inc-securities-litigation or call to speak to our claim center toll-free at (844) 367-9658.
About the Lawsuit
IntelliPharmaCeutics and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) the Company failed to perform human abuse testing to support the New Drug Application (“NDA”) for Rexista; (ii) the Company failed to include studies conducted to support Rexista’s label claims regarding human abuse by various pathways; (iii) the Company was not submitting data to sufficiently support approval of the NDA; and (iv) as a result of the foregoing, IntelliPharmaCeutics’ financial statements were materially false and misleading at all relevant times.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. ClaimsFiler's team of experts monitor the securities class action landscape and cull information from a variety of sources to ensure comprehensive coverage across a broad range of financial instruments.
To learn more about ClaimsFiler, visit www.claimsfiler.com.
